Currently, the main prognostic biomarkers used in the management of prostate cancer are molecularly defined, including prostate specific antigen (PSA), Gleason score, D’Amico risk group, National Comprehensive Cancer Network (NCCN) risk groups, etc. More recently, genomic classifiers have been developed to facilitate a better precision medicine in patients with prostate cancer. During his lecture at the 2021 BMUC meeting, Dr. Daniel E. Spratt gave an overview of the current biomarker landscape in patients with prostate cancer and made a case for the use of these novel genomic classifiers.